Edwards Lifesciences (EW) Tops Q3 EPS by 8c; Issues Solid Outlook

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.80, $0.08 better than the analyst estimate of $0.72. Revenue for the quarter came in at $607.4 million versus the consensus estimate of $546.1 million.

Edwards Lifesciences sees Q4 2014 EPS of $0.89-$0.95, versus the consensus of $0.95. Edwards Lifesciences sees Q4 2014 revenue of $575-615 million, versus the consensus of $586.91 million.

Edwards Lifesciences sees FY2014 EPS of $3.33-$3.39, versus the consensus of $3.3. Edwards Lifesciences sees FY2014 revenue of $2.05-2.25 billion, versus the consensus of $2.24 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Fort Technology posts 49% revenue rise in first half of 2026
• Star Equity to acquire Harte Hanks for $5 per share in cash and stock